CRL — Charles River Laboratories International Income Statement
0.000.00%
Last trade - 00:00- $5.63bn
- $7.73bn
- $4.05bn
- 91
- 62
- 40
- 69
Annual income statement for Charles River Laboratories International, fiscal year end - December 28th, USD millions except per share, conversion factor applied.
2020 December 26th | 2021 December 25th | 2022 December 31st | 2023 December 30th | 2024 December 28th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,924 | 3,540 | 3,976 | 4,129 | 4,050 |
| Cost of Revenue | |||||
| Gross Profit | 1,074 | 1,335 | 1,463 | 1,529 | 1,408 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2,491 | 2,928 | 3,305 | 3,389 | 3,823 |
| Operating Profit | 433 | 613 | 671 | 741 | 227 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 447 | 481 | 623 | 581 | 93.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 365 | 399 | 493 | 480 | 25.3 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 364 | 391 | 486 | 475 | 10.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 364 | 391 | 486 | 475 | 10.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 7.63 | 7.98 | 9.3 | 7.92 | 4.27 |